DeshwalH, WeinsteinT, SulicaR. Advances in the management of pulmonary arterial hypertension. J Investig Med2021;69:1270–80.doi:10.1136/jim-2021-002027
2.
SimonneauG, MontaniD, CelermajerDS, . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J2019;53:1801913.doi:10.1183/13993003.01913-2018http://www.ncbi.nlm.nih.gov/pubmed/30545968
3.
HemnesAR, BeckGJ, NewmanJH, . PVDOMICS: a multi-center study to improve understanding of pulmonary vascular disease through phenomics. Circ Res2017;121:1136–9.doi:10.1161/CIRCRESAHA.117.311737http://www.ncbi.nlm.nih.gov/pubmed/29074534
4.
TangWHW, WilcoxJD, JacobMS, . Comprehensive diagnostic evaluation of cardiovascular physiology in patients with pulmonary vascular disease: insights from the PVDOMICS program. Circ Heart Fail2020;13:e006363. doi:10.1161/CIRCHEARTFAILURE.119.006363http://www.ncbi.nlm.nih.gov/pubmed/32088984
5.
McGoonMD, MillerDP. Reveal: a contemporary us pulmonary arterial hypertension registry. Eur Respir Rev2012;21:8–18.doi:10.1183/09059180.00008211http://www.ncbi.nlm.nih.gov/pubmed/22379169
6.
GalièN, BarberàJA, FrostAE, . Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med2015;373:834–44.doi:10.1056/NEJMoa1413687http://www.ncbi.nlm.nih.gov/pubmed/26308684
7.
WangZ, BierEA, SwaminathanA, . Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. Eur Respir J2019;54:1900831.doi:10.1183/13993003.00831-2019http://www.ncbi.nlm.nih.gov/pubmed/31619473
8.
WilsonM, KeeleyJ, KingmanM, . Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulm Circ2020;10:2045894020950186. doi:10.1177/2045894020950186http://www.ncbi.nlm.nih.gov/pubmed/33062258
9.
BenzaRL, KanwarMK, RainaA, . Development and validation of an abridged version of the reveal 2.0 risk score calculator, reveal Lite 2, for use in patients with pulmonary arterial hypertension. Chest2021;159:337–46.doi:10.1016/j.chest.2020.08.2069http://www.ncbi.nlm.nih.gov/pubmed/32882243
10.
van de VeerdonkMC, MarcusJT, WesterhofN, . Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest2015;147:1063–71.doi:10.1378/chest.14-0701http://www.ncbi.nlm.nih.gov/pubmed/25376008
11.
KanwarMK, Gomberg-MaitlandM, HoeperM, . Risk stratification in pulmonary arterial hypertension using Bayesian analysis. Eur Respir J2020;56:2000008.doi:10.1183/13993003.00008-2020http://www.ncbi.nlm.nih.gov/pubmed/32366491
12.
ScottJV, GarnettCE, KanwarMK, . Enrichment benefits of risk algorithms for pulmonary arterial hypertension clinical trials. Am J Respir Crit Care Med2021;203:726–36.doi:10.1164/rccm.202002-0357OChttp://www.ncbi.nlm.nih.gov/pubmed/32937078
13.
KloseH, ChinKM, EwertR, . Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. Respir Res2021;22:34. doi:10.1186/s12931-020-01594-8http://www.ncbi.nlm.nih.gov/pubmed/33536021
14.
ShapiroS, BourgeRC, PozellaP, . Implantable system for treprostinil: a real-world patient experience study. Pulm Circ2020;10:2045894020907881. doi:10.1177/2045894020907881http://www.ncbi.nlm.nih.gov/pubmed/32363029
15.
RoscignoR, VaughnT, AndersonS, . Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil. Pulm Circ2020;10:2045894020971509. doi:10.1177/2045894020971509http://www.ncbi.nlm.nih.gov/pubmed/33282202
16.
HumbertM, McLaughlinV, GibbsJSR, . Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med2021;384:1204–15.doi:10.1056/NEJMoa2024277http://www.ncbi.nlm.nih.gov/pubmed/33789009
17.
van de VeerdonkMC, KindT, MarcusJT, . Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol2011;58:2511–9.doi:10.1016/j.jacc.2011.06.068http://www.ncbi.nlm.nih.gov/pubmed/22133851
